European Journal of Immunology · 2023 · 11 citations · 17 references
Life SciencesImmunologyOncologyImmuno-oncology PharmacotherapyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesBiomarker-guided ImmunotherapyCytotoxic T Lymphocyte ResponsesImmuno-oncology BiomarkersTherapy Response AssessmentAtezolizumab TherapyCd8+ Tumor-infiltrating LymphocytesImmune Biomarkers In CancerImmune Cell ActivationImmune Checkpoint Inhibitor BiomarkersImmune Therapy Response AssessmentPeripheral Blood Immune BiomarkersPeripheral Blood Lymphocyte Analysis
Due to the lack of biomarkers predictive of response to atezolizumab-bevacizumab, the standard of care for advanced HCC, we analyzed baseline and early on-treatment variation of peripheral lymphocyte populations of 37 prospective patients treated by atezolizumab-bevacizumab and in 15 prospective patients treated by sorafenib or lenvatinib (TKIs). RNAseq analysis followed by RT-PCR validation on patients-derived PBMC was also performed. At first imaging, re-evaluation 13 patients receiving atezolizumab-bevacizumab, showed an objective response, 17 stable disease, while 7 were nonresponders. Baseline CD8+ and CD8+PD-L1+ peripheral lymphocytes were lower in responders versus nonresponders (T-test, p = 0.012 and 0.004, respectively). At 3 weeks, 28 of 30 responders displayed a rise of CD8+PD1+ lymphocytes with a positive mean fold change of 4.35 (±5.6 SD), whereas 6 of 7 nonresponders displayed a negative fold change of 0.89 (±0.84 SD). These changes were not observed in patients treated by TKIs. TRIM56, TRIM16, TRIM64, and Ki67 mRNAs were validated as upregulated in responders versus nonresponders after 3 weeks after treatment start, providing possible evidence of immune activation. Baseline CD8+ and CD8+PD-L1+ peripheral lymphocytes and early changes in CD8+PD1+ lymphocytes predict response to atezolizumab-bevacizumab providing noninvasive markers to complement clinical practice in the very early phases of treatment of HCC patients.
17
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · New England Journal of Medicine · 2020 · 7.2K citations · Full text
Medicine, Oncology, Pharmacotherapy +12
Tadashi Yokosuka, Masako Takamatsu, Wakana Kobayashi-Imanishi et al. · The Journal of Experimental Medicine · 2012 · 1.2K citations · Full text
Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity
Fumiya Hirano, Katsumi Kaneko, Hideto Tamura et al. · Cancer Research · 2005 · 1K citations · Full text
Medicine, Immunology, Oncology +17